IMB-202 / IMBiologics - LARVOL DELTA

A highly selective and novel TCR-like antibody, IMB-202, targeting NK and T cell immune checkpoint for enhanced cancer immunotherapy (AACR 2025) - "Furthermore, its rapid internalization of IMB-202 supports its potential as an antibody-drug conjugate (ADC) candidate, with robust internalization also observed in the ePENDY platform format.These findings highlight IMB-202 as a promising alternative to existing ICIs and as a first-in-class therapy, targeting a novel immune checkpoint ligand with exceptional selectivity. Additionally, IMB-202 demonstrates significant potential for superior anti-tumor efficacy, with the versatility to be applied across various therapeutic modalities."

Oncology